Shots:
- Arbor to receive an up front in cash & is eligible to receive an additional ~$1.2B on achievement of milestones across up to 7 programs along with royalties on sales on products emerges from the collaboration. Vertex will also invest in Arbor in the form of a convertible note
- Vertex get rights to use Arbor’s technology to research & develop ex vivo engineered cell therapies for T1D, beta thalassaemia, sickle-cell disease, and other diseases
- The collaboration follows the 2018 agreement & will expands Vertex’s cell and gene therapies targeting multiple serious diseases. The agreement also determines the versatility and strength of Arbor’s platform
Click here to read full press release/ article | Ref: Globe Newswire | Image: Stat News
The post Vertex Expands its 2018 Agreement with Arbor to Develop Novel Ex Vivo Engineered Cell Therapies first appeared on PharmaShots.
